EA201190337A1 - Способ лечения - Google Patents

Способ лечения

Info

Publication number
EA201190337A1
EA201190337A1 EA201190337A EA201190337A EA201190337A1 EA 201190337 A1 EA201190337 A1 EA 201190337A1 EA 201190337 A EA201190337 A EA 201190337A EA 201190337 A EA201190337 A EA 201190337A EA 201190337 A1 EA201190337 A1 EA 201190337A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
solvates
patient
methods
pharmaceutically acceptable
Prior art date
Application number
EA201190337A
Other languages
English (en)
Inventor
Меган М. Маклафлин
Джон Ирвинг Вурзельманн
Чунь-Фан Сю
Original Assignee
Глаксо Вэллкам Мэньюфэкчуринг Пти Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Вэллкам Мэньюфэкчуринг Пти Лтд. filed Critical Глаксо Вэллкам Мэньюфэкчуринг Пти Лтд.
Publication of EA201190337A1 publication Critical patent/EA201190337A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к способам лечения возрастной макулярной дегенерации у пациента путем введения пазопаниба или его фармацевтически приемлемых солей или сольватов.
EA201190337A 2009-07-16 2010-07-16 Способ лечения EA201190337A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22611309P 2009-07-16 2009-07-16
PCT/US2010/042211 WO2011009016A1 (en) 2009-07-16 2010-07-16 Treatment method

Publications (1)

Publication Number Publication Date
EA201190337A1 true EA201190337A1 (ru) 2012-06-29

Family

ID=43449814

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201190337A EA201190337A1 (ru) 2009-07-16 2010-07-16 Способ лечения

Country Status (14)

Country Link
US (1) US20120165354A1 (ru)
EP (1) EP2453748A4 (ru)
JP (1) JP2012533562A (ru)
KR (1) KR20120049267A (ru)
CN (1) CN102573477A (ru)
AU (1) AU2010273254A1 (ru)
BR (1) BR112012001030A2 (ru)
CA (1) CA2768237A1 (ru)
EA (1) EA201190337A1 (ru)
IL (1) IL217492A0 (ru)
MX (1) MX2012000706A (ru)
SG (1) SG178032A1 (ru)
WO (1) WO2011009016A1 (ru)
ZA (1) ZA201109517B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201201808A (en) * 2010-01-06 2012-01-16 Glaxo Wellcome Mfg Pte Ltd Treatment method
US20130023550A1 (en) * 2010-05-05 2013-01-24 Glaxo Wellcome Manufacturing Pte, Ltd Pharmaceutical compositions and methods of making same
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
EA201400064A1 (ru) 2011-06-28 2014-05-30 Байер Хелфкеэ Ллк Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
US20140235678A1 (en) 2011-06-28 2014-08-21 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Sorafenib
CN104582685A (zh) 2012-06-25 2015-04-29 拜尔健康护理有限责任公司 含有舒尼替尼的局部眼科药物组合物
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
CA2981021C (en) 2015-03-26 2020-11-17 Eyekor, Llc Image analysis
CN105800652B (zh) * 2016-02-06 2017-08-25 杭州锦江集团有限公司 低铝硅比铝土矿的干法烧成方法
CN112730725A (zh) * 2019-10-28 2021-04-30 齐鲁制药有限公司 一种测定盐酸培唑帕尼中氯离子含量的分析方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2597411C (en) * 2005-02-14 2014-08-12 University Of Iowa Research Foundation Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration
US20080255000A1 (en) * 2005-11-02 2008-10-16 Dogulu Cigdem F Method Evolved for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd)
MX2008006379A (es) * 2005-11-29 2009-03-03 Smithkline Beecham Corp Metodo de tratamiento.
JP5431151B2 (ja) * 2006-07-13 2014-03-05 ユニバーシティー オブ アイオワ リサーチ ファンデーション 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬
US20090263801A1 (en) * 2008-01-04 2009-10-22 Duke University Phenotype-Genotype Relationship in Age-Related Macular Degeneration

Also Published As

Publication number Publication date
IL217492A0 (en) 2012-02-29
WO2011009016A1 (en) 2011-01-20
ZA201109517B (en) 2013-05-29
BR112012001030A2 (pt) 2019-09-24
AU2010273254A1 (en) 2012-02-02
EP2453748A4 (en) 2013-01-02
KR20120049267A (ko) 2012-05-16
JP2012533562A (ja) 2012-12-27
CA2768237A1 (en) 2011-01-20
US20120165354A1 (en) 2012-06-28
CN102573477A (zh) 2012-07-11
SG178032A1 (en) 2012-03-29
EP2453748A1 (en) 2012-05-23
MX2012000706A (es) 2012-06-01

Similar Documents

Publication Publication Date Title
EA201190337A1 (ru) Способ лечения
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
EA201290603A1 (ru) Способ лечения
BR112014009418A2 (pt) macrociclos peptidomiméticos
UA113627C2 (xx) Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
UA111841C2 (uk) Сполуки бензотіазолу та їх фармацевтичне застосування
PH12013501436A1 (en) Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
UA110983C2 (ru) Производная 1,2,3,4-тетрагидрохинолина, пригодная для лечения диабета
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
PH12014500386A1 (en) Combination treatment for hepatitis c
IN2014CN04634A (ru)
PH12014500967A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
EA201200428A1 (ru) Композиция и способ для лечения ожирения
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
PH12014500381A1 (en) Therapeutic methods
NZ598490A (en) Treatment of macular degeneration
PH12014502065A1 (en) Vesicular formulations
MX2013007055A (es) Derivados de sanglifehrina y metodos para su produccion.
TW200744627A (en) Methods for the treatment of macular degeneration and related eye conditions
GB201107576D0 (en) Novel compounds and methods for use in medicine
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
MX2013008137A (es) Procedimientos para tratar la prostatitis.
MX2014013491A (es) Metodos para mantener, tratar o mejorar la funcion cognitiva.